ZNTL – zentalis pharmaceuticals, inc. - common stock (US:NASDAQ)
Stock Stats
News
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
Form 8-K Zentalis Pharmaceuticals For: Mar 26
Form S-3 Zentalis Pharmaceuticals
Form 10-K Zentalis Pharmaceuticals For: Dec 31
Form 8-K Zentalis Pharmaceuticals For: Mar 15
Form SCHEDULE 13G/A Zentalis Pharmaceuticals Filed by: EVENTIDE ASSET MANAGEMENT, LLC
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.